As an investor whom, I guess, has made two mistakes so far, I am not panicked in any way about my mission, although I feel I have wasted some time being patient. Today, the other stock I hold in my portfolio, a company called Cleveland BioLabs Inc.(CBLI) announced third quarter earnings today. Like many biopharmaceutical companies, stock price has nothing at all to do with earnings as it does with prospective news. CBLI posted a lesser net loss than a year ago but less revenues also. This company has never been profitable since its inception,so why would anyone invest in CBLI? Let me give you my theory. Some institutions hold substantial amounts of stock in this company. These institutions make a living trading securities. Institutions trading CBLI have not covered their short positions in this company for the simple fact that there is no volume changing hands at current price levels. Today's volume was a little higher than the median volume traded in CBLI but nothing to get excited about after its earnings announcement today. Until I see excessive volume at these price levels will I begin to get enthused. My feeling is that based on what the information given in today;s earnings report,there is a positive hint of potential growth. A Phase 1 study of Entolimod, the drug that CBLI is putting its hopes,will be completed in the first half of 2015. My hope is that the price of CBLI will at least double by the first half of next year based on the potential success of these trials.
Investing in CBLI is not for the feint of heart but neither is investing in general. To be successful investor,one has to think like the institutions who hold the inventory of stocks in the companyone is invested..and even then you are guessing human nature.
Wednesday, November 5, 2014
Sunday, November 2, 2014
Off We Go
Friday was a good day for investors in Service Source International (SREV). What makes me feel better about Friday's trading day was the way the institutions in SREV distributed the stock during the day. Although the trading volume was a little less than expected, this leads me to believe that in the short-term, more shares will be distributed at higher levels. I do not expect the price of SREV to go much higher than $5.00 or $5.50 for the next three months when the next earnings report is announced at the end of January. What I find kind of peculiar is that Zacks or thestreet.com did not mention why the stck was up on Friday. To me, it is probably another indication that market makers are quietly taking SREV higher. I feel better that SREV is closer to my $4.60 entry price and hope to be making a profit along with the institutions that trade and hold this stock for their investment accounts.
The other stock I hold is Cleveland BioLabs Inc. (CBLI). I purchased 300 shares of this biotechnology stock back in April, the same day I purchased SREV. I purchased these shares at %0.50 per share as my speculation hunch so to speak. The earnings are atrocious as it is awaiting FDA approval of its main cancer drug. I really don't care what the drug is but I am intensely fascinated at the politics of these pharmaceutical companies and the games that the United States Federal Government plays a part. I feel that , like SREV, the quarterly earnings report will be the driving force in the price of CBLI stock. Unlike SREV, the FDA can, at any time release information that will let investors know if CBLI's cancer drug will pass one of its trials.
CBLI trades today, November 2, 2014 at $0.51 per share. Since I have own CBLI, the stock price has traded as high as $0.72 per share and $9.37 per share. On Wednesday November 5, CBLI will announce its third quarter earnings and it will be interesting to see what happens to CBLI's stock price if anything. The volume is quite light which to me means more of the same $0.40 to &0.50 trading range. My goal in this stock is to see it double and never look back. I am still at ground zero on this one. Let;s wait until Wednesday.
Meanwhile, I will begin looking for a stock for my son to invest. With interest rates so low,mhe wanys his money to work harder than 0.1% annually. He's young and wants his money to work hard for him. The stock market journey continues...
The other stock I hold is Cleveland BioLabs Inc. (CBLI). I purchased 300 shares of this biotechnology stock back in April, the same day I purchased SREV. I purchased these shares at %0.50 per share as my speculation hunch so to speak. The earnings are atrocious as it is awaiting FDA approval of its main cancer drug. I really don't care what the drug is but I am intensely fascinated at the politics of these pharmaceutical companies and the games that the United States Federal Government plays a part. I feel that , like SREV, the quarterly earnings report will be the driving force in the price of CBLI stock. Unlike SREV, the FDA can, at any time release information that will let investors know if CBLI's cancer drug will pass one of its trials.
CBLI trades today, November 2, 2014 at $0.51 per share. Since I have own CBLI, the stock price has traded as high as $0.72 per share and $9.37 per share. On Wednesday November 5, CBLI will announce its third quarter earnings and it will be interesting to see what happens to CBLI's stock price if anything. The volume is quite light which to me means more of the same $0.40 to &0.50 trading range. My goal in this stock is to see it double and never look back. I am still at ground zero on this one. Let;s wait until Wednesday.
Meanwhile, I will begin looking for a stock for my son to invest. With interest rates so low,mhe wanys his money to work harder than 0.1% annually. He's young and wants his money to work hard for him. The stock market journey continues...
Subscribe to:
Posts (Atom)